Advertisement

Herztherapeutika

  • Thomas Eschenhagen

Zusammenfassung

Herzglykoside und Koronarmittel gehen in ihren Verordnungszahlen unvermindert zurück, während sich Antiarrhythmika auf niedrigem Niveau stabilisiert haben. Für alle drei Gruppen fehlt eine klare Evidenz für prognostisch günstige Wirkungen, dazu haben Antiarrhythmika und Herzglykoside eine niedrige therapeutische Breite mit potentiell lebensbedrohlichen Nebenwirkungen. Die Zahl der häufig verwendeten Substanzen in der Gruppe Herztherapeutika ist inzwischen überschaubar, was im Sinne der Arzneimittelsicherheit zu begrüßen ist.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aarnoudse AL, Dieleman JP, Stricker BH (2007): Age- and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf 30: 431–436PubMedGoogle Scholar
  2. Ahmed A, Waagstein F, Pitt B, White M, Zannad F, Young JB, Rahimtoola S (2009): Effectiveness of Digoxin in Reducing One-Year Mortality in Chronic Heart Failure in the Digitalis Investigation Group Trial. Am J Cardiol 103: 82–87PubMedCentralPubMedGoogle Scholar
  3. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators (2005): Amiodaron or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352: 225–237PubMedCrossRefGoogle Scholar
  4. Castagno D, Petrie MC, Claggett B, McMurray J (2012): Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 33: 1137–1141PubMedCrossRefGoogle Scholar
  5. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse HF;PALLAS Investigators, (2011): Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365: 2268–2276Google Scholar
  6. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al. (1991): Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 324: 781–788Google Scholar
  7. ESC/DGK Pocket-Leitlinie für das Management von Vorhofflimmern (2012). http://leitliniendgk.org/files/2012_Pocket-Leitlinien_Vorhofflimmern.pdf
  8. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G (2004): Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 25: 1385–1394PubMedCrossRefGoogle Scholar
  9. Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008): Ivabradine for patients with stable coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372: 807–816PubMedGoogle Scholar
  10. Hirayama A, Kodama K, Yui Y, Nonogi H, Sumiyoshi T, Origasa H, Hosoda S, Kawai C, Japan Multicenter Investigation for Cardiovascular Diseases-Mochida Investigators (2003): Effect of trapidil on cardiovascular events in patients with coronary artery disease (results from the Japan Multicenter Investigation for Cardiovascular Diseases-Mochida [JMIC-M]). Am J Cardiol 92: 789–793Google Scholar
  11. Hocini M, Jais P, Sanders P, Takahashi Y, Rotter M, Rostock T, Hsu LF, Sacher F, Reuter S, Clementy J, Haissaguerre M (2005): Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study. Circulation 112: 3688–3696PubMedCrossRefGoogle Scholar
  12. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators (2009): Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360: 668–678Google Scholar
  13. Kassenärztliche Bundesvereinigung (2012): Verordnungssteuerung. Pentalong® ist nicht verordnungsfähig. Internet: www.kbv.de/40842.htmlGoogle Scholar
  14. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, Ravens U, Samol A, Steinbeck G, Treszl A, Wegscheider K, Breithardt G (2012): Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 380: 238–246PubMedGoogle Scholar
  15. Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H, Amlie J, Carlsen J; Dronedarone Study Group (2008): Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358: 2678–2687Google Scholar
  16. Lehmann G, Reiniger G, Beyerle A, Schomig A (1998): Clinical comparison of antiischemic efficacy of isosorbide dinitrate and molsidomine. J Cardiovasc Pharmacol 31: 25–30PubMedGoogle Scholar
  17. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM (2010): A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS Study. J Cardiovasc Electrophysiol 21: 597–605PubMedCrossRefGoogle Scholar
  18. Maresta A, Balducelli M, Latini R, Bernardi G, Moccetti T, Sosa C, Barlera S, Varani E, Ribeiro da Silva EE, Monici Preti A, Maggioni AP; STARC II Investigators (2005): Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting. Catheter Cardiovasc Interv. 64: 375–382PubMedCrossRefGoogle Scholar
  19. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M et al. ESC Committee for Practice Guidelines (2012): ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 33: 1787–1847Google Scholar
  20. Meinertz T, Lehmacher W for the Trapidil/ISDN Study Group (2006): Trapidil is as effective as isosorbidedinitrate for treating stable angina pectoris – a multinational, multicenter, double-blind, randomized study. Clin Res Cardiol. 95: 217–223PubMedCrossRefGoogle Scholar
  21. Mest HJ (1990): Trapidil: a potent inhibitor of platelet aggregation. J Drug Dev 3: 143–149Google Scholar
  22. Morrow DA, Scirica BM, Sabatine MS, de Lemos JA, Murphy SA, Jarolim P, Theroux P, Bode C, Braunwald E (2010): B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol 55: 1189–1196PubMedCrossRefGoogle Scholar
  23. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML for the Multicenter Automatic Defibrillator Implantation Trial II Investigators (2002): Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 346: 877–883PubMedCrossRefGoogle Scholar
  24. Nationale Versorgungsleitlinie Chronische Herzinsuffizienz. März 2012. http://www.versorgungsleitlinien.de/themen/herzinsuffizienz/pdf/nvl_hi_lang.pdf
  25. Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, Dluzniewski M, Hatala R, Opolski G, Muller HW, Meinertz T; SOPAT Investigators (2004): Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. Eur Heart J 25: 1395–1404PubMedCrossRefGoogle Scholar
  26. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003): Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289: 871–878PubMedGoogle Scholar
  27. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O’Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators. (2008): Rhythm control versus rat control for atrial fibrillation and heart failure. N Engl J Med 358: 2667–2677Google Scholar
  28. Sanders GD, Hlatky MA, Owens DK (2005): Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353: 1471–1480PubMedCrossRefGoogle Scholar
  29. Schmiedl S, Szymanski J, Rottenkolber M, Hasford J, Thürmann PA (2007): Re: Age- and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf 30: 1171–1173; author reply 1173–1174CrossRefGoogle Scholar
  30. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators (2010): Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376: 875–885PubMedGoogle Scholar
  31. The Digitalis Investigation Group (1997): The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525–533Google Scholar
  32. Tardif JC (2007): Clinical results of I(f ) current inhibition by ivabradine. Drugs 67 Suppl 2: 35–41PubMedGoogle Scholar
  33. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K (2005): Efficacy of ivabradine, a new selective I(f ) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26: 2529–2536PubMedGoogle Scholar
  34. Vaughan Williams EM (1975): Classification of antidysrhythmic drugs. Pharmac Ther B 1: 115–138Google Scholar
  35. Wagner F, Gohlke-Barwolf C, Trenk D, Jähnchen E, Roskamm H (1991): Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and shortterm administration in stable angina pectoris. Eur Heart J 12: 994–999PubMedGoogle Scholar
  36. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators (2002): A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347: 1825–1833PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Thomas Eschenhagen
    • 1
  1. 1.Institut für Experimentelle und Klinische PharmakologieUniversitäts-Krankenhaus EppendorfHamburg

Personalised recommendations